This company is no longer active
Dividendos de Sesen Bio
Dividendo controles de criterios 0/6
Información clave
n/a
Rentabilidad por dividendo
n/a
Ratio de pago
| Rentabilidad media de la industria | 2.8% |
| Próxima fecha de pago de dividendos | n/a |
| Fecha ex dividendo | n/a |
| Dividendo por acción | n/a |
| Beneficios por acción | -US$0.098 |
| Rentabilidad por dividendo prevista a 3 años | n/a |
Últimas actualizaciones de dividendos
Recent updates
Sesen Bio and Carisma Therapeutics announce merger agreement
Sep 21Sesen Bio GAAP EPS of -$0.16 misses by $0.03
Aug 08Sesen Bio granted additional time period for regaining compliance
Jul 27Sesen Bio slips after decision to pause U.S. studies for lead asset
Jul 18Sesen Bio: Another Net-Net Biopharma Exploring Strategic Alternatives
Jun 02We Think Sesen Bio (NASDAQ:SESN) Needs To Drive Business Growth Carefully
Apr 17
We're Keeping An Eye On Sesen Bio's (NASDAQ:SESN) Cash Burn Rate
Dec 05Sesen Bio: Interesting Price Drop After CRL
Nov 24Sesen Bio: Hoping For An Easy Revalidation Of Vicineum By 2022
Nov 17Sesen Bio: The Road Ahead
Aug 23Earnings Update: Here's Why Analysts Just Lifted Their Sesen Bio, Inc. (NASDAQ:SESN) Price Target To US$7.00
Aug 12Sesen Bio: Binary Event Approaching
Jun 13Sesen Bio inks global supply partnership with Qilu Pharmaceutical
Jun 02Sesen Bio EPS misses by $0.27
May 10Sesen Bio: Long-Term And Short-Term Potential In Advance Of Its First PDUFA
May 07News Flash: 3 Analysts Think Sesen Bio, Inc. (NASDAQ:SESN) Earnings Are Under Threat
Feb 18Sesen announces positive FDA meeting for vicineum's marketing application
Feb 01Is Sesen Bio (NASDAQ:SESN) In A Good Position To Deliver On Growth Plans?
Jan 26Sesen Bio/Qilu Pharma's Vicineum IND application accepted for review in China
Jan 13Sesen Bio files US application for its Vicineum in bladder cancer
Dec 21Sesen Bio, Inc.'s (NASDAQ:SESN) Profit Outlook
Dec 21
Sesen Bio: A Look At Vicineum's Potential
Nov 29Sesen Bio, Inc. 2020 Q3 - Results - Earnings Call Presentation
Nov 09Estabilidad y crecimiento de los pagos
Obteniendo datos sobre dividendos
Dividendo estable: Insufficient data to determine if SESN's dividends per share have been stable in the past.
Dividendo creciente: Insufficient data to determine if SESN's dividend payments have been increasing.
Rentabilidad por dividendo vs. Mercado
| Rentabilidad por dividendo de Sesen Bio vs. Mercado |
|---|
| Segmento | Rentabilidad por dividendo |
|---|---|
| Empresa (SESN) | n/a |
| Suelo de mercado 25% (US) | 1.5% |
| Techo de mercado 25% (US) | 4.6% |
| Media de la industria (Biotechs) | 2.8% |
| Previsión de analistas en 3 años (SESN) | n/a |
Dividendo destacado: Unable to evaluate SESN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
Alto dividendo: Unable to evaluate SESN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Pago de beneficios a los accionistas
Cobertura de los beneficios: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Pago en efectivo a los accionistas
Cobertura de flujo de caja: Unable to calculate sustainability of dividends as SESN has not reported any payouts.